Targeting the “undruggable”: Laigo Bio secures €11.5 million to advance its SureTAC protein degradation platform

Laigo Bio, an Utrecht-based firm introducing unique and extremely set apart treatments utilizing its exclusive SureTAC accuracy membrane layer healthy protein deterioration system, has actually effectively elevated EUR11.5 million in Seed funding.

The financing round was co-led by Kurma Allies and Curie Funding. The various other capitalists were Argobio Workshop, Angelini Ventures (the equity capital arm of Angelini Industries), Eurazeo, theOncode Bridge Fund, ROM Utrecht area, and UK-based Cancer Cells Study Horizons, the translation subsidiary of Cancer cells Study UK.

Laigo Biography’s beginnings additionally connect back to Argobio, the French BioTech start-up workshop that released in 2021 with €50 million committed to creating and developing pioneering therapeutic spinouts throughout oncology, immunology, uncommon illness and neurological conditions.

“ This Seed financing is a solid recommendation of both the clinical structure and the special capacity of our method allowing careful deterioration of membrane-bound targets associated with autoimmune and inflammatory illness,” states Dr Matthew Baker, President of Laigo Biography.

In 2025, numerous European start-ups running in nearby areas of immunology, swelling and immuno-oncology additionally protected financing, emphasizing constant– though careful– financial investment task in this field.

Austria’s Graph Therapeutics elevated EUR3 million in pre-Seed funding to progress its AI-enabled swelling and immunology drug-discovery system. France-based Exeliom Biosciences included EUR2.85 million in a Collection An expansion to advance its microbiome-based immunotherapies for cancer cells and immuno-inflammatory problems. At the same time, UK firm T-Therapeutics protected a EUR27.5 million Collection An expansion to create its T-cell receptor bispecific system for autoimmune condition and oncology.

Entirely, these rounds stand for about EUR33 million streaming right into associated fields throughout 2025.

Within this landscape, Laigo Biography’s EUR11.5 million Seed round places the Dutch start-up amongst a concentrated friend of European firms establishing next-generation immunology and oncology modern technologies.

“ With these sources, we are well placed to start exploration initiatives in auto-immunity and to progress our oncology programs via preclinical growth. Our group stays concentrated on attaining essential preclinical turning points and proceeding our first-in-class lead programs towards very early medical assessment, to supply transformative treatments for individuals,” includes Dr Baker

Laigo Biography was established by the Oncode Institute, along with the Oncode Bridge Fund, and Argobio Workshop, a worldwide BioTech startup workshop released by Kurma Allies, BPI France and Angelini Ventures.

Laigo Biography is leveraging E3 ligase internalisation for the careful deterioration of membrane-bound targets associated with autoimmune and inflammatory illness. Its exclusive SureTAC system develops bispecific antibodies that target the ideal set of E3 ligase and disease-causing target to boost ubiquitination and lysosomal deterioration of the target healthy protein with a high level of uniqueness.

Destruction of the target healthy protein accomplishes much deeper restraint of condition paths, while saving the preferable features of the target cell.

Surface Area Elimination Targeting Chimeras (SureTAC), established by Prof Madelon Maurice’s lab at the UMC Utrecht, are exclusive healing prospects for targeted deterioration of membrane layer healthy proteins, that have actually been confirmed as condition vehicle drivers yet have actually avoided medication exploration, and were long thought about ‘undruggable’.

“ Kurma is delighted to sustain a business with such an encouraging innovation system targeting condition paths that have actually long been considered undruggable,” states Thierry Laugel, Chairman of the Monitoring Board of Argobio and Handling Companion at Kurma Allies.

The firm will certainly utilize the earnings to progress its SureTAC oncology programs in the direction of medical growth, and to speed up exploration and growth of its 3 SureTAC immunology prospect healing programs for picked autoimmune and immunology signs and graft denial.

In its oncology programs targeted at the immune checkpoint PD-L1 and VEGF, and a hard-to-drug Wnt path receptor, Laigo Biography has actually apparently revealed that its SureTAC deterioration innovation causes in vivo and artificial insemination effectiveness. SureTACs reveal a high level of selectivity for targeting unhealthy cells, causing enhanced poisoning and safety and security.

Laigo Biography means to progress its oncology programs inside up until conclusion of preclinical research studies prior to teaming up with pharmaceutical companions to bring them right into the center.

Laigo Biography additionally reveals the consultation of Dr Matthew Baker, the present acting President, as its chief executive officer.

“ Curie Funding is happy to sustain growth of Laigo Biography’s SureTac special system innovation as a result of its guarantee in resolving really particular healing targets in illness with high unmet clinical demand,” states Mariëtte Roesink, Handling Companion of Curie Funding.

The message Targeting the “undruggable”: Laigo Bio secures €11.5 million to advance its SureTAC protein degradation platform showed up initially on EU-Startups.